Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, Hammond JM, Le Pogam S, Nájera I, Passe S, Piekarska A, Rodriguez I, Zeuzem S, Chu T; ANNAPURNA study investigators. Jensen DM, et al. Among authors: zeuzem s. Liver Int. 2016 Apr;36(4):505-14. doi: 10.1111/liv.12997. Epub 2015 Dec 12. Liver Int. 2016. PMID: 26519669 Clinical Trial.
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J. Rasenack J, et al. Among authors: zeuzem s. Pharmacoeconomics. 2003;21(5):341-9. doi: 10.2165/00019053-200321050-00005. Pharmacoeconomics. 2003. PMID: 12627987 Clinical Trial.
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.
Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S. Kronenberger B, et al. Among authors: zeuzem s. Eur J Gastroenterol Hepatol. 2007 Aug;19(8):639-46. doi: 10.1097/MEG.0b013e3281ac20ca. Eur J Gastroenterol Hepatol. 2007. PMID: 17625432 Clinical Trial.
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
Snoeck E, Hadziyannis SJ, Puoti C, Swain MG, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuzem S. Snoeck E, et al. Among authors: zeuzem s. Liver Int. 2008 Jan;28(1):61-71. doi: 10.1111/j.1478-3231.2007.01603.x. Epub 2007 Oct 25. Liver Int. 2008. PMID: 17971091
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA; Globe Study Group. Lai CL, et al. Among authors: zeuzem s. N Engl J Med. 2007 Dec 20;357(25):2576-88. doi: 10.1056/NEJMoa066422. N Engl J Med. 2007. PMID: 18094378 Free article. Clinical Trial.
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein C; Hep-Net B/C Co-infection Study Group. Potthoff A, et al. Among authors: zeuzem s. J Hepatol. 2008 Nov;49(5):688-94. doi: 10.1016/j.jhep.2008.03.028. Epub 2008 Apr 29. J Hepatol. 2008. PMID: 18490077 Clinical Trial.
Novel hepatitis C drugs in current trials.
Kronenberger B, Welsch C, Forestier N, Zeuzem S. Kronenberger B, et al. Among authors: zeuzem s. Clin Liver Dis. 2008 Aug;12(3):529-55, viii. doi: 10.1016/j.cld.2008.03.001. Clin Liver Dis. 2008. PMID: 18625427 Review.
1,172 results